HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bob Kronemyer

Latest From Bob Kronemyer

Canadian Firm Aims To Cast Wide Net To Grow Using Marine Algae Phytoplankton In Nutrition

Marine algae phytoplankton is abundant with numerous vitamins and minerals and is found on the ocean’s surface. Blugenics Innovations markets Karen brand powder and tablet line with proprietary phytoplankton ingredient it also provides to other firms.

Dietary Supplements Ingredients

Study Finds Data Scarce Where US FDA Wants To Gauge Hemp Safety – Reproductive Toxicity

First systematic mapping study of safety concerns for consumer use of cannabidiol identifies knowledge gaps for reproductive and developmental toxicity. No traditional, guideline-compliant developmental and reproductive toxicity study was available in the public domain through December 2020.

Cannabidiol CBD FDA

Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.

Market Intelligence Cancer

Start-Up Spotlight: Tyto Care Brings Medical Exams To Homes

Israeli-based start-up Tyto Care markets TytoHome, a device that allows consumers to check their ears, breathing and temperature from home and share the findings with a clinician for remote diagnosis.

Start-Up Spotlight StartUps and SMEs

Market Intel: 3D Bioprinting Forges Ahead With Mini Human Heart, Human Tissue

The race continues to heat up in the bioprinting space over which players will first reach the finish line in gaining approval for tissue and organ replacements. Research organizations and companies worldwide are in various states of development for these milestones in regenerative medicine, ranging from bioprinting skin to a mini human heart. But regulatory hurdles and quality testing could be formidable.

Market Intelligence Innovation

Market Intel: Large Providers Focus On Hemodialysis Home Care; New Incentive By Presidential Executive Order

Momentum is rising for patients with chronic kidney disease to be treated with hemodialysis in the comfort of their own home as opposed to traveling several days a week to a freestanding clinic. Manufacturers, government and payers are paving the way for a higher home-therapy adoption rate. That said, many patients remain unsuitable for home care and the large volume of water needed to operate hemodialysis can be logistically daunting.

Market Intelligence Renal
See All
UsernamePublicRestriction

Register